Seres Therapeutics, Inc.MCRBNASDAQ
Loading
Price to Sales: Premium ValuationElevated
Percentile Rank100
5Y CAGR+23.2%
Studio
Year-over-Year Change

Price-to-sales ratio

5Y CAGR
+23.2%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
2.8x
Strong expansion
Streak
1 yr
Consecutive growthElevated
PeriodValueYoY Change
2025167.07-
20240.00-
20230.00-
20220.00-100.0%
20215.27-91.0%
202058.85+939.1%
20195.66-13.1%
20186.52-49.0%
201712.78-29.5%
201618.12-